ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy

Bai, Ziyi; Zhou, Yao; Ye, Zifan; Xiong, Jialong; Lan, Hongying; Wang, Feng*北京理工大学; 哈尔滨医科大学
Frontiers in Immunology2022-1-14DOI: 10.3389/fimmu.2021.808964
49被引10阅读
引用收藏
分享

摘要

The clinical success of immunotherapy has revolutionized the treatment of cancer patients, bringing renewed attention to tumor-infiltrating lymphocytes (TILs) of various cancer types. Immune checkpoint blockade is effective in patients with mismatched repair defects and high microsatellite instability (dMMR-MSI-H) in metastatic colorectal cancer (CRC), leading the FDA to accelerate the approval of two programmed cell death 1 (PD-1) blocking antibodies, pembrolizumab and nivolumab, for treatment of dMMR-MSI-H cancers. In contrast, patients with proficient mismatch repair and low levels of microsatellite stability or microsatellite instability (pMMR-MSI-L/MSS) typically have low tumor-infiltrating lymphocytes and have shown unsatisfied responses to the immune checkpoint inhibitor. Different TILs environments reflect different responses to immunotherapy, highlighting the complexity of the underlying tumor-immune interaction. Profiling of TILs fundamental Indication would shed light on the mechanisms of cancer-immune evasion, thus providing opportunities for the development of novel therapeutic strategies. In this review, we summarize phenotypic diversities of TILs and their connections with prognosis in CRC and provide insights into the subsets-specific nature of TILs with different MSI status. We also discuss current clinical immunotherapy approaches based on TILs as well as promising directions for future expansion, and highlight existing clinical data supporting its use.

学科与关键词

关键词
tumor-infiltrating lymphocytestertiary lymphoid structuresmicrosatellite instabilityimmunotherapycolorectal cancer
相关
加载中…
  • How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
    Wang, Qianyu; Shen, Xiaofei; Chen, Gang*; Du, Junfeng*International Journal of Cancer, 2023, 153(4): 709-722.被引 1
  • Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
    Du, Fenqi; Liu, Yanlong*Journal of Clinical Laboratory Analysis, 2022, 36(1): e24141.被引 9
  • Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis
    Wang, Ren; Lian, Jie; Wang, Xin; Pang, Xiangyi; Xu, Benjie; Tang, Shuli; Shao, Jiayue; Lu, Haibo*BIOMOLECULES AND BIOMEDICINE, 2023, 23(2): 198-208.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-01-14
卷期
第 12 卷
页码
808964
DOI
10.3389/fimmu.2021.808964
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [31770827, 21736002]

作者

  • B

    Bai, Ziyi (第一作者)

    harbin med univ · beijing inst technol

  • Z

    Zhou, Yao

    harbin med univ

查看全部 6 位作者收起作者
  • Y

    Ye, Zifan

    beijing inst technol

  • X

    Xiong, Jialong

    beijing inst technol

  • L

    Lan, Hongying

    beijing inst technol

  • W

    Wang, Feng (通讯)

    beijing inst technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417